American scientists have described a new drug that can prevent the severe course and lethal outcome of bird flu infection.
This is a new antitumor immunotherapy, the peculiarity of which is that the drug affects a stable section of the bird flu virus. This helps to fight even new strains of the virus.
The authors of the development, researchers from the University of Pittsburgh led by Professor Douglas Reed, have already tested the drug on primates. As a result, it turned out that antibodies MEDI8852 retain a protective effect for 8-12 weeks.
Scientists note that their method of therapy can be quickly adapted to treat humans, as this antibody has already undergone clinical trials against human strains of influenza.